These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15974923)

  • 1. Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors.
    Dickey CA; Eriksen J; Kamal A; Burrows F; Kasibhatla S; Eckman CB; Hutton M; Petrucelli L
    Curr Alzheimer Res; 2005 Apr; 2(2):231-8. PubMed ID: 15974923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.
    Blair LJ; Sabbagh JJ; Dickey CA
    Expert Opin Ther Targets; 2014 Oct; 18(10):1219-32. PubMed ID: 25069659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.
    Dickey CA; Kamal A; Lundgren K; Klosak N; Bailey RM; Dunmore J; Ash P; Shoraka S; Zlatkovic J; Eckman CB; Patterson C; Dickson DW; Nahman NS; Hutton M; Burrows F; Petrucelli L
    J Clin Invest; 2007 Mar; 117(3):648-58. PubMed ID: 17304350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
    Bhat R; Tummalapalli SR; Rotella DP
    J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
    Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
    Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein.
    Tortosa E; Santa-Maria I; Moreno F; Lim F; Perez M; Avila J
    J Alzheimers Dis; 2009; 17(2):319-25. PubMed ID: 19363271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 activator Aha1 drives production of pathological tau aggregates.
    Shelton LB; Baker JD; Zheng D; Sullivan LE; Solanki PK; Webster JM; Sun Z; Sabbagh JJ; Nordhues BA; Koren J; Ghosh S; Blagg BSJ; Blair LJ; Dickey CA
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9707-9712. PubMed ID: 28827321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linking HSP90 target occupancy to HSP70 induction and efficacy in mouse brain.
    Thirstrup K; Sotty F; Montezinho LC; Badolo L; Thougaard A; Kristjánsson M; Jensen T; Watson S; Nielsen SM
    Pharmacol Res; 2016 Feb; 104():197-205. PubMed ID: 26731018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of Hsp90-induced oligomerizaton of Tau.
    Weickert S; Wawrzyniuk M; John LH; Rüdiger SGD; Drescher M
    Sci Adv; 2020 Mar; 6(11):eaax6999. PubMed ID: 32201713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau triage decisions mediated by the chaperone network.
    Cook C; Petrucelli L
    J Alzheimers Dis; 2013; 33 Suppl 1():S145-51. PubMed ID: 22596270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome.
    Opattova A; Filipcik P; Cente M; Novak M
    J Alzheimers Dis; 2013; 33(2):339-48. PubMed ID: 22936006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHIP-ping away at tau.
    Goryunov D; Liem RK
    J Clin Invest; 2007 Mar; 117(3):590-2. PubMed ID: 17332887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stressing Out Hsp90 in Neurotoxic Proteinopathies.
    Inda C; Bolaender A; Wang T; Gandu SR; Koren J
    Curr Top Med Chem; 2016; 16(25):2829-38. PubMed ID: 27072699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.
    Ganesh T; Min J; Thepchatri P; Du Y; Li L; Lewis I; Wilson L; Fu H; Chiosis G; Dingledine R; Liotta D; Snyder JP; Sun A
    Bioorg Med Chem; 2008 Jul; 16(14):6903-10. PubMed ID: 18571929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat Shock Proteins in Alzheimer's Disease: Role and Targeting.
    Campanella C; Pace A; Caruso Bavisotto C; Marzullo P; Marino Gammazza A; Buscemi S; Palumbo Piccionello A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening strategies to identify HSP70 modulators to treat Alzheimer's disease.
    Repalli J; Meruelo D
    Drug Des Devel Ther; 2015; 9():321-31. PubMed ID: 25609918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.
    Luo W; Dou F; Rodina A; Chip S; Kim J; Zhao Q; Moulick K; Aguirre J; Wu N; Greengard P; Chiosis G
    Proc Natl Acad Sci U S A; 2007 May; 104(22):9511-6. PubMed ID: 17517623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
    Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
    Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.